// App-Quantinova.ai

P276 : Comparative effects of ixekizumab (IXE) vs adalimumab (ADA) across PsA patients defined by baseline characteristics: week 24 outcomes from SPIRIT-H2H

Researchers

Presenter

  • Hasan Tahir

Principal Investigators

  • Andrew J Bradley

  • Mani H Nassab

  • Burkhard Mller

  • Josef S Smolen

  • Christophe Sapin

  • Carla F Dionello

  • Gabriella Meszaros

Medical Centers

  • Royal Free London NHS Trust, Royal Free London NHS Trust, London, UNITED KINGDOM

  • Eli Lilly and Company, Indianapolis, IN

  • Department of Rheumatology, Immunology and Allergology, Inselspital – University Hospital Bern, Bern, SWITZERLAND

  • Universidade Federal do Rio de Janeiro, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRAZIL

Locations

  • United Kingdom

  • United States

  • Switzerland

  • Austria

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Dactylitis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Malondialdehyde

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03151551

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved